MabGenesis, Inc.

MabGenesis, Inc.

TTSE:653A
666.00
JPY
+37.00
(+5.88%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Shinjo Katsuhiro
Full Time Employees
13
Sector
Health technology
Industry
Biotechnology
Address
3 Chome-7-18 Shinyokohama Yokohama KN Japan 222-0033
IPO Date
Nov 2, 2026
Business
MabGenesis, Inc. operates as a biopharmaceutical company that develops therapeutic monoclonal antibody drugs in the human and animal fields. It develops antibody libraries as MOURA Libraries in terms of functionality and completeness, and highly efficient monoclonal antibody isolation technology. The company was founded on June. 3, 2019 and is headquartered in Yokohama, Japan.